arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Autolus Therapeutics plc

AUTL
$2.10 ▲ +0.10 (+4.73%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Autolus Therapeutics plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $558.9M
Dividend Yield
Revenue Growth 191.9%
Op. Margin -227.0%
ROIC -55.4%
FCF / Share $-0.26
Trailing P/E
Price / Book 5.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$26.22M
↑ +191.9%
Net Income Profit after all expenses
$-71.60M
↓ -2.0%
Operating Margin Operating profit as % of sales
-227.0%
↑ +23.9% 0th
FCF / Share Free cash flow per share
$-0.26
↑ +18.9%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
4
Financial Health
33
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 30 quarters